Deactylase inhibition in myeloproliferative neoplasms

Investigational New Drugs

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Mithraprabhu, Sridurga ^a   Grigoriadis, George ^a,b   Khong, Tiffany ^a   Spencer, Andrew ^a  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

Author keywords

Chronic myelogenous leukemia; Deactylase inhibition; Epigenetic therapy; Myeloproliferative neoplasms

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 AZA 2' DEOXYCYTIDINE; APICIDIN; BCR ABL PROTEIN; BUTYRIC ACID; DACINOSTAT; GAMMA INTERFERON; GIVINOSTAT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; ROMIDEPSIN; SORAFENIB; TRICHOSTATIN A; VALPROIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL FUNCTION; CELL PROLIFERATION; CHRONIC EOSINOPHILIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; EOSINOPHILIC LEUKEMIA; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC EPIGENESIS; HUMAN; IMMUNE RESPONSE; MYELOID METAPLASIA; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC MASTOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT;

ANIMALS; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS;

EID: 78651358562     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-010-9590-4     Document Type: Article

References (101)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) World health organisation classification of tumours of haemopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC) Press, Lyon
2. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer Statistics, 2007 CA Cancer J Clin 57 43 66 10.3322/canjclin.57.1.43 17237035
3. CG Geary 2000 The story of chronic myeloid leukaemia Br J Haematol 110 2 11 1:STN:280:DC%2BD3cvisVKjtw%3D%3D 10.1046/j.1365-2141.2000.02137.x 10930974 (Pubitemid 30625590)
4. M Baccarini D Russo G Rosti G Martinelli 2003 Interferon-alfa for chronic myeloid leukemia Semin Hematol 40 22 33
5. M Baccarini G Saglio L Goldman, et al. 2006 Evolving concepts in the management of chronc myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net Blood 108 1809 1820 10.1182/blood-2006-02- 005686 (Pubitemid 44394987)
6. A Gratwohl R Brand J Apperley, et al. 2006 Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Haematologica 91 513 521 16533723
7. BJ Druker F Guilhot SG O'Brien, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 1:CAS:528:DC%2BD28Xht12ntrzM 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
8. HM Kantarjian M Talpaz F Giles S O'Brien J Cortes 2006 New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance Ann Intern 145 913 923 (Pubitemid 351639967)
9. E Weisberg PW Manley SW Cowan-Jacob A Hochhaus JD Griffin 2007 Second generation inhibitors of BCR-ABL for the treatment of imatinib resistant chronic myeloid leukaemia Nat Rev Cancer 7 345 256 1:CAS:528:DC%2BD2sXksFSiu7o%3D 10.1038/nrc2126 17457302 (Pubitemid 46652483)
10. Y Dai, et al. 2004 A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2 J Biol Chem 279 33 34227 34239 1:CAS:528:DC%2BD2cXmvFent7g%3D 10.1074/jbc. M402290200 15175350 (Pubitemid 39318046)
11. NJ Donato, et al. 2004 Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia Cancer Res 64 2 672 677 1:CAS:528:DC%2BD2cXmsVagsw%3D%3D 10.1158/0008-5472.CAN-03-1484 14744784 (Pubitemid 38120909)
12. SM Lee, et al. 2007 Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors J Pharmacol Exp Ther 322 3 1084 1092 1:CAS:528: DC%2BD2sXpslKrtr4%3D 10.1124/jpet.107.124461 17569822 (Pubitemid 47295793)
13. AM Vannucchi P Guglielmelli A Rambaldi C Bogani T Barbui 2009 Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives J Cell Mol Med 13 1437 1450 1:CAS:528:DC%2BD1MXhtlGns7bP 10.1111/j.1582-4934.2009.00827.x 19522842
14. AV Jones RT Silver Waghorn, et al. 2006 Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha Blood 107 3339 3341 1:CAS:528:DC%2BD28Xjs1OksL0%3D 10.1182/blood-2005-09-3917 16352805
15. JJ Kiladjian C Chomienne P Fenaux 2008 Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms Leukemia 122 1990 1998 10.1038/leu.2008.280
16. JJ Kiladjian B Cassinat S Chevret, et al. 2008 Pegylated Interferon-alfa-2a induces complete haematological and molecular responses with low toxicity in polycythemia vera Blood 112 3065 3072 1:CAS:528: DC%2BD1cXht1OmtbfE 10.1182/blood-2008-03-143537 18650451
17. RA Mesa S Verstovek C Rivera, et al. 2009 5-Azacitidine has limited therapeutic activity in myelofibrosis Leukemia 23 180 182 1:CAS:528: DC%2BD1MXkvVeisQ%3D%3D 10.1038/leu.2008.136 18509350
18. F Cervantes R Mesa G Barosi 2007 New and old treatment modalities in primary myelofibrosis Cancer J 13 377 383 1:CAS:528:DC%2BD2sXhsVGgtr%2FE 10.1097/PPO.0b013e31815a7c0a 18032975
19. RA Mesa JK Camoriano SM Geyer, et al. 2007 A phase II trial of tifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia Leukemia 21 1964 1970 1:CAS:528:DC%2BD2sXptlSrs7Y%3D 10.1038/sj.leu.2404816 17581608 (Pubitemid 47299971)
20. RA Mesa S Verstovsek C Rivera, et al. 2008 Bortezomib therapy in myelofibrosis: a phase II clinical trial Leukemia 22 1636 1638 1:CAS:528:DC%2BD1cXpslSnurk%3D 10.1038/leu.2008.32 18305559
21. A Tefferi TL Lasho RA Mesa, et al. 2007 Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions Leukemia 21 1827 1828 1:CAS:528:DC%2BD2sXnvVeltrg%3D 10.1038/sj.leu.2404711 17460705 (Pubitemid 47086775)
22. A Quintas-Cardama K Vaddi P Liu, et al. 2010 Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Blood 115 3109 3117 1:CAS:528:DC%2BC3cXltlWqsr8%3D 10.1182/blood-2009-04-214957 20130243
23. M Esteller 2007 Epigenetic gene silencing in cancer: the DNA hypermethylome Hum Mol Genet 16 Spec No 1 50 59 10.1093/hmg/ddm018 (Pubitemid 47241842)
24. MF Fraga, et al. 2005 Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer Nat Genet 37 4 391 400 1:CAS:528:DC%2BD2MXislCmurg%3D 10.1038/ng1531 15765097
25. O Witt, et al. 2009 HDAC family: what are the cancer relevant targets? Cancer Lett 277 1 8 21 1:CAS:528:DC%2BD1MXjtFOhsL4%3D 10.1016/j.canlet.2008.08. 016 18824292
26. S Timmermann, et al. 2001 Histone acetylation and disease Cell Mol Life Sci 58 5-6 728 736 1:CAS:528:DC%2BD3MXlt1ait7s%3D 10.1007/PL00000896 11437234
27. S Shi HC Calhoun F Xia, et al. 2006 JAK signalling globally counteracts heterochromatic gene silencing Nat Genet 38 1071 1076 1:CAS:528: DC%2BD28XovVWjtrw%3D 10.1038/ng1860 16892059 (Pubitemid 44325935)
28. Q Zhang HY Wang A Woetmannn, et al. 2006 STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T cells Blood 108 1058 1064 1:CAS:528:DC%2BD28XnvFajur8%3D 10.1182/blood-2005-08-007377 16861352 (Pubitemid 44154645)
29. A Tefferi 2008 Epigenetic alterations and anti-epigenetic therapy in myelofibrosis Leuk Lymphoma 49 2231 2232 10.1080/10428190802578866 19052966
30. JC Wang, et al. 2008 Enhanced histone deacetylase enzyme activity in primary myelofibrosis Leuk Lymphoma 49 12 2321 2327 1:CAS:528:DC%2BD1cXhsVGqu7fK 10.1080/10428190802527699 19052980
31. N Fourcouclas J Li DC Gilby, et al. 2008 Methylation of the suppressor of cytokine signalling 3 gene (SOCS3) in myeloproliferative disorders Haematologica 93 1635 1644 10.3324/haematol.13043
32. D Capello C Deambrogi D Rossi, et al. 2008 Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders Br J Haematol 141 504 511 1:CAS:528: DC%2BD1cXnt1eisLo%3D 10.1111/j.1365-2141.2008.07072.x 18318760 (Pubitemid 351550557)
33. M Fernandez-Mercado V Cebrian B Euba, et al. 2008 Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms Leuk Res 32 1638 1640 1:CAS:528: DC%2BD1cXntlGgsLc%3D 10.1016/j.leukres.2008.03.014 18440067
34. E Jost ON do E Dahl 2007 Epigenetic alterations complement mutations of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders Leukemia 21 505 510 1:CAS:528:DC%2BD2sXhvFWksLs%3D 10.1038/sj.leu.2404513 17230231
35. P Guglielmelli R Zini C Bogani, et al. 2007 Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1) Stem Cells 25 165 173 1:CAS:528:DC%2BD2sXhvVGjtLo%3D 10.1634/stemcells.2006-0351 16990584 (Pubitemid 46052987)
36. V Rosti M Massa AM Vannucchi, et al. 2007 The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia Blood Cells Mol Dis 38 280 286 1:CAS:528:DC%2BD2sXjvFegs7k%3D 10.1016/j.bcmd.2007.01.003 17350297 (Pubitemid 46518174)
37. C Bogani V Ponziani P Gugliemelli, et al. 2008 Hypermethylation of CXCR4 promoter in the CD34+ cells from patients with primary myelofibrosis Stem Cells 26 1920 1930 1:CAS:528:DC%2BD1cXhtVKmt77F 10.1634/stemcells.2008-0377 18511598
38. X Wang W Zhang T Ishii, et al. 2008 Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin modifying agents Blood 112 101A
39. LR Silverman EP Demakos BL Peterson, et al. 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 2429 2440 1:CAS:528: DC%2BD38XksFakur8%3D 10.1200/JCO.2002.04.117 12011120 (Pubitemid 34525728)
40. P Fenaux GJ Mufti V Santini, et al. 2007 Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR) Blood 110 817
41. A Quintas-Cardama W Tong H Kantarjian, et al. 2008 A phase II study of 5-Azacitidine for patients with primary and post essential thrombocythemia/ polycythemia vera myelofibrosis Leukemia 22 965 970 1:CAS:528: DC%2BD1cXlvVSrtr4%3D 10.1038/leu.2008.91 18385750 (Pubitemid 351689878)
42. M Haberland, et al. 2009 The many roles of histone deacetylases in development and physiology: implications for disease and therapy Nat Rev Genet 10 1 32 42 1:CAS:528:DC%2BD1cXhsFWis7bI 10.1038/nrg2485 19065135
43. M Haberland, et al. 2009 Genetic dissection of histone deacetylase requirement in tumor cells Proc Natl Acad Sci USA 106 19 7751 7755 1:CAS:528:DC%2BD1MXmt1ams7o%3D 10.1073/pnas.0903139106 19416910
44. H Lehrmann, et al. 2002 Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation Adv Cancer Res 86 41 65 1:CAS:528:DC%2BD38XpsVyisrw%3D 10.1016/S0065-230X(02)86002-X 12374280
45. A Mai, et al. 2005 Histone deacetylation in epigenetics: an attractive target for anticancer therapy Med Res Rev 25 3 261 309 1:CAS:528: DC%2BD2MXjslGit7w%3D 10.1002/med.20024 15717297 (Pubitemid 40489663)
46. S Spange, et al. 2009 Acetylation of non-histone proteins modulates cellular signalling at multiple levels Int J Biochem Cell Biol 41 1 185 198 1:CAS:528:DC%2BD1cXhsVWnu7zP 10.1016/j.biocel.2008.08.027 18804549
47. MA Glozak, et al. 2005 Acetylation and deacetylation of non-histone proteins Gene 363 15 23 1:CAS:528:DC%2BD2MXht1Klu7%2FN 10.1016/j.gene.2005.09. 010 16289629 (Pubitemid 41691888)
48. MA Glozak, et al. 2007 Histone deacetylases and cancer Oncogene 26 37 5420 5432 1:CAS:528:DC%2BD2sXovFeku7Y%3D 10.1038/sj.onc.1210610 17694083 (Pubitemid 47255924)
49. TA Miller, et al. 2003 Histone deacetylase inhibitors J Med Chem 46 24 5097 5116 1:CAS:528:DC%2BD3sXosVCktbg%3D 10.1021/jm0303094 14613312 (Pubitemid 37414179)
50. JE Bolden, et al. 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 9 769 784 1:CAS:528:DC%2BD28XptVCltrY%3D 10.1038/nrd2133 16955068 (Pubitemid 44348499)
51. S Minucci, et al. 2006 Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 1 38 51 1:CAS:528:DC%2BD28Xht1GgsA%3D%3D 10.1038/nrc1779 16397526 (Pubitemid 43054973)
52. WS Xu, et al. 2007 Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 37 5541 5552 1:CAS:528:DC%2BD2sXovFersrY%3D 10.1038/sj.onc.1210620 17694093 (Pubitemid 47255934)
53. H Brinkmann, et al. 2001 Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts J Biol Chem 276 25 22491 22499 1:CAS:528:DC%2BD3MXkvVams7Y%3D 10.1074/jbc.M100206200 11304533
54. A Burgess, et al. 2004 Histone deacetylase inhibitors specifically kill nonproliferating tumour cells Oncogene 23 40 6693 6701 1:CAS:528: DC%2BD2cXntFGnu7o%3D 10.1038/sj.onc.1207893 15235588 (Pubitemid 39280001)
55. AJ Burgess, et al. 2001 Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity Mol Pharmacol 60 4 828 837 1:CAS:528:DC%2BD3MXnt1ersrk%3D 11562446
56. L Qiu, et al. 2000 Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells Mol Biol Cell 11 6 2069 2083 1:CAS:528:DC%2BD3cXkt1Sisbc%3D 10848630
57. A Insinga, et al. 2005 Mechanisms of selective anticancer action of histone deacetylase inhibitors Cell Cycle 4 6 741 743 1:CAS:528: DC%2BD28XhslCqtr8%3D 10.4161/cc.4.6.1717 15908787
58. MW Deininger, et al. 2000 BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia Cancer Res 60 7 2049 2055 1:CAS:528:DC%2BD3cXisVymsrc%3D 10766197
59. DG Savage, et al. 2002 Imatinib mesylate-a new oral targeted therapy N Engl J Med 346 9 683 693 1:CAS:528:DC%2BD38XhsFOjsro%3D 10.1056/NEJMra013339 11870247 (Pubitemid 34815874)
60. ME Gorre, et al. 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 5531 876 880 1:CAS:528:DC%2BD3MXlvVKrsbs%3D 10.1126/science.1062538 11423618 (Pubitemid 32743979)
61. NP Shah, et al. 2002 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2 117 125 1:CAS:528:DC%2BD38XmslSks7c%3D 10.1016/S1535-6108(02)00096-X 12204532 (Pubitemid 41039112)
62. DG Aguilera, et al. 2009 Dasatinib in chronic myeloid leukemia: a review Ther Clin Risk Manag 5 2 281 289 1:CAS:528:DC%2BD1MXpt1yltL4%3D 19536317
63. R Swords, et al. 2009 Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib Drug Des Devel Ther 3 89 101 1:CAS:528:DC%2BD1MXoslSms7c%3D 19920925
64. W Fiskus, et al. 2006 Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells Blood 108 2 645 652 1:CAS:528:DC%2BD28XntFehtbk%3D 10.1182/blood-2005-11-4639 16537804 (Pubitemid 44061366)
65. P George, et al. 2005 Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3 Blood 105 4 1768 1776 1:CAS:528:DC%2BD2MXhsVGjsL4%3D 10.1182/blood-2004-09-3413 15514006 (Pubitemid 40223701)
66. A Morotti, et al. 2006 Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells Cancer 106 5 1188 1196 1:CAS:528:DC%2BD28Xis1agtL8%3D 10.1002/cncr.21725 16444746
67. R Nimmanapalli, et al. 2003 Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells Cancer Res 63 16 5126 5135 1:CAS:528: DC%2BD3sXms12ntro%3D 12941844
68. R Nimmanapalli, et al. 2003 Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells Blood 101 8 3236 3239 1:CAS:528:DC%2BD3sXjtFCqtbg%3D 10.1182/blood-2002-08-2675 12446442 (Pubitemid 36858020)
69. Y Xu, et al. 2005 The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines Int J Mol Med 15 1 169 172 1:CAS:528:DC%2BD2MXmsFeiug%3D%3D 15583844
70. Y Dai, et al. 2008 Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate Blood 112 3 793 804 1:CAS:528:DC%2BD1cXpsVais78%3D 10.1182/blood-2007-10-116376 18505786
71. JS Carew, et al. 2007 Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance Blood 110 1 313 322 1:CAS:528:DC%2BD2sXnsVaitrw%3D 10.1182/blood-2006-10-050260 17363733 (Pubitemid 47026849)
72. W Fiskus, et al. 2006 Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells Clin Cancer Res 12 19 5869 5878 1:CAS:528:DC%2BD28XhtVartbnM 10.1158/1078-0432.CCR-06-0980 17020995 (Pubitemid 44629620)
73. C Yu, et al. 2005 Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells Leukemia 19 9 1579 1589 1:CAS:528:DC%2BD2MXovVOjurk%3D 10.1038/sj.leu.2403868 16015388 (Pubitemid 43090402)
74. Kalle AM et al (2010) Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). Leuk Res
75. WK Rasheed, et al. 2007 Histone deacetylase inhibitors in cancer therapy Expert Opin Investig Drugs 16 5 659 678 1:CAS:528:DC%2BD2sXks1aht78%3D 10.1517/13543784.16.5.659 17461739 (Pubitemid 46729100)
76. W Fiskus, et al. 2008 Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells Clin Cancer Res 14 19 6106 6115 1:CAS:528:DC%2BD1cXhtF2nurvO 10.1158/1078-0432.CCR- 08-0721 18829489
77. G Dasmahapatra, et al. 2007 Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation Clin Cancer Res 13 14 4280 4290 1:CAS:528:DC%2BD2sXnvVChtro%3D 10.1158/1078-0432.CCR-07-0835 17634558 (Pubitemid 47108172)
78. C Yu, et al. 2003 The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571 Blood 102 10 3765 3774 1:CAS:528:DC%2BD3sXptVymtb0%3D 10.1182/blood-2003-03-0737 12893773 (Pubitemid 37409399)
79. SJ Park, et al. 2009 Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells Exp Cell Res 315 11 1809 1818 1:CAS:528:DC%2BD1MXms1Oqur8%3D 10.1016/j.yexcr.2009.02.024 19268463
80. T Kawano, et al. 2004 Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect Anticancer Res 24 5A 2705 2712 1:CAS:528:DC%2BD2cXhtVSjsL3L 15517875
81. S Okabe, et al. 2007 Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis Stem Cells Dev 16 3 503 514 1:CAS:528:DC%2BD2sXnt1Wltr8%3D 10.1089/scd.2007.9994 17610380 (Pubitemid 47016235)
82. B Kircher, et al. 2009 Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ALL and CML cells in vitro Eur J Haematol 83 1 48 56 1:CAS:528:DC%2BD1MXos1yiu7c%3D 10.1111/j.1600-0609.2009.01242.x 19226363
83. D Grebenova, et al. 2006 The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells Blood Cells Mol Dis 37 3 210 217 1:CAS:528:DC%2BD28Xht1CisL7K 10.1016/j.bcmd.2006.08.001 16978890 (Pubitemid 44781085)
84. E Rabizadeh, et al. 2007 Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line Leuk Res 31 8 1115 1123 1:CAS:528:DC%2BD2sXmtlamtrw%3D 10.1016/j.leukres.2006.12.015 17267032
85. B Zhang, et al. 2010 Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate Cancer Cell 17 5 427 442 10.1016/j.ccr.2010.03.011 20478526
86. N Bissonnette, et al. 1998 p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage Oncogene 16 26 3461 3469 1:CAS:528:DyaK1cXks1ensbg%3D 10.1038/sj.onc.1201899 9692554
87. A Suzuki, et al. 1999 Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21 Oncogene 18 5 1239 1244 1:CAS:528:DyaK1MXhsVyrt7Y%3D 10.1038/sj.onc.1202409 10022130 (Pubitemid 29085997)
88. F Gesbert, et al. 2000 BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway J Biol Chem 275 50 39223 39230 1:CAS:528: DC%2BD3cXptFSrs7o%3D 10.1074/jbc.M007291200 11010972 (Pubitemid 32058940)
89. P Bali, et al. 2005 Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 29 26729 26734 1:CAS:528:DC%2BD2MXmt1Ggs7w%3D 10.1074/jbc.C500186200 15937340 (Pubitemid 41040705)
90. R Rao, et al. 2008 HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells Blood 112 5 1886 1893 1:CAS:528:DC%2BD1cXhtVylu7jI 10.1182/blood-2008-03-143644 18591380
91. HY Cohen, et al. 2004 Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis Mol Cell 13 5 627 638 1:CAS:528: DC%2BD2cXis1Kktbs%3D 10.1016/S1097-2765(04)00094-2 15023334 (Pubitemid 38368121)
92. LJ Juan, et al. 2000 Histone deacetylases specifically down-regulate p53-dependent gene activation J Biol Chem 275 27 20436 20443 1:CAS:528:DC%2BD3cXkvVyhsrs%3D 10.1074/jbc.M000202200 10777477 (Pubitemid 30457621)
93. S Kume, et al. 2006 Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation Free Radic Biol Med 40 12 2175 2182 1:CAS:528:DC%2BD28XlvF2hu74%3D 10.1016/j.freeradbiomed.2006.02.014 16785031 (Pubitemid 43903102)
94. LG Wang, et al. 2008 De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc Int J Oncol 33 2 375 380 1:CAS:528:DC%2BD1cXhtV2lsb3J 18636159
95. V Guerini, et al. 2008 The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) Leukemia 22 4 740 747 1:CAS:528:DC%2BD1cXks12rt7g%3D 10.1038/sj.leu.2405049 18079739 (Pubitemid 351552623)
96. J Shi, et al. 2007 Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis Cancer Res 67 13 6417 6424 1:CAS:528:DC%2BD2sXnsVyqtbw%3D 10.1158/0008-5472.CAN-07-0572 17616702 (Pubitemid 47037526)
97. Rambaldi A, Dellacasa CM, Salmoiraghi S et al (2008) A phase 2A study of the histone-deacetlase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. 112:110A
98. Y Wang, et al. 2009 Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells Blood 114 24 5024 5033 1:CAS:528:DC%2BD1MXhsF2gsb%2FI 10.1182/blood-2009-05-222133 19828702
99. DJ DeAngelo A Spencer T Fischer, et al. 2009 Activity of oral panobinostat (LBH589) in patients with myelofibrosis Blood 114 2898
100. J Mascareenhas X Wang A Rodriguez 2009 A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post-PV/ET MF) Blood 114 308 10.1182/blood-2009-06-230037
101. J Lee 2009 Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis Ann Hematol 88 7 699 700 10.1007/s00277-008-0640-3 19030859